Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

FN Media Group Presents USA News Group News Commentary

VANCOUVER, British Columbia, Sept. 26, 2023 /PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer among individuals younger than 55 years. Another study published in JAMA Network Open showed that early-onset cancer in people younger than 50 rose over the last decade, with gastrointestinal cancers seeing the fastest increase. This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now. Among the ongoing efforts that are drawing more attention in the pancreatic cancer space have been the developments coming from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC.TO), Merus N.V. (NASDAQ:MRUS), Guardant Health, Inc. (NASDAQ:GH), Medtronic plc (NYSE:MDT), and even NVIDIA Corporation (NASDAQ:NVDA).